NASDAQ:APVO Aptevo Therapeutics Q3 2026 Earnings Results & Report $0.40 -0.01 (-2.37%) Closing price 11/20/2026 04:00 PM EasternExtended Trading$0.41 +0.00 (+1.21%) As of 11/20/2026 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Aptevo Therapeutics missed analyst earnings expectations in its Q3 2026 results, released November 16, 2026. The company reported EPS of -$5.19 versus the -$3.71 consensus estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ3 2026Report DateNovember 16, 2026TimeBefore Market Opens Aptevo Therapeutics EPS ResultsActual EPS-$5.19Consensus EPS -$3.71Beat/MissMissed by -$1.48One Year Ago EPSN/AEPS Beat Rate1 of last 4 quartersAptevo Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AConference Call ResourcesSEC FilingEarnings HistoryCompany Profile Aptevo Therapeutics Q3 2026 Earnings FAQ Did Aptevo Therapeutics beat earnings estimates for Q3 2026? Aptevo Therapeutics (NASDAQ:APVO) reported earnings of -$5.19 per share for Q3 2026, missing the consensus estimate of -$3.71. The report was announced on Monday, November 16, 2026. Aptevo Therapeutics Earnings HeadlinesAPVO: RAINIER Phase 1b Dose Optimization Study Completion by Year-End 2026November 19 at 4:33 PM | finance.yahoo.comAptevo Provides 3Q26 Business Update Highlighting Growing Momentum for Mipletamig and Reports Third Quarter Financial ResultsNovember 16, 2026 | finance.yahoo.comToday's free pick (on me)Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one lesser known company. With plans filed for 1,000,000 new satellites, that licensing fee could scale dramatically. Analyst Dylan says the stock could move by December 8th.November 21 at 1:00 AM | Behind the Markets (Ad)Aptevo Reports 79% Remission Rate in TP53-Mutated AMLNovember 16, 2026 | quiverquant.comQAptevo Therapeutics Announces Warrant Exercise Financing AgreementNovember 12, 2026 | tipranks.comAptevo Therapeutics Announces Closing of Existing Warrants Exercise for $3.0 Million Gross ProceedsNovember 12, 2026 | finanznachrichten.deSee More Aptevo Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Aptevo Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Aptevo Therapeutics and other key companies, straight to your email. Email Address About Aptevo TherapeuticsAptevo Therapeutics (NASDAQ:APVO) is a biotechnology company focused on developing immunotherapies, particularly treatments for cancer. Its research uses engineered antibody-based approaches intended to direct or activate the immune system against disease. The company’s programs have included APVO436, a bispecific antibody designed to connect CD3-positive T cells with CD123-positive leukemia cells and investigated as a potential treatment for acute myeloid leukemia. Aptevo has also worked on other immune-targeting candidates, including programs designed to stimulate immune responses against tumors. Aptevo was established in 2016 as a spin-off from Emergent BioSolutions. The company is based in Seattle, Washington, and its work is centered on research and development rather than a broad portfolio of marketed medicines.View Aptevo Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles If NVIDIA Tightens Its Wallet, These 3 Stocks Could Feel ItAirfares Are Up, Flights Are Tight: 3 Airline Stocks Facing a Winter TestHard Drives Were Left for Dead, But Seagate and Western Digital Are SoaringPalo Alto Networks' Q1 Beat Gives Its Stock Rally Another Reason to RunGrand Theft Auto VI Arrives: Why Take-Two Is a Waiting GameWalmart Earnings Change the Narrative as Digital Growth Lifts OutlookWhatever Happens to Copper Next, These 3 Investments Offer Different Ways to Play It Upcoming Earnings Hewlett Packard Enterprise (11/23/2026)Medtronic (11/24/2026)Analog Devices (11/24/2026)Autodesk (11/24/2026)Dell Technologies (11/24/2026)Deere & Company (11/25/2026)CrowdStrike (12/1/2026)Marvell Technology (12/1/2026)Bank Of Montreal (12/2/2026)Bank of Nova Scotia (12/2/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.